Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
What would be your post-operative therapy approach for a high grade neuroendocrine carcinoma of the thymus?
What if there was mediastinal nodal involvement?
Answer from: Radiation Oncologist at Academic Institution
Postoperative RT.
Sign in or Register to read more
13071
Related Questions
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
What is your approach to adjuvant RT or chemoRT in LS-SCLC s/p lobectomy with N1 disease?
How do you manage a symptomatic fluid collection in the chest wall following SBRT?
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?